Top Markets
#1 Akedo Akedo +70.80%
#2 MEET48 MEET48 +28.68%
#3 Bitway Bitway +22.15%
#4 Astar Astar +18.51%
#5 VeThor VeThor +16.97%
#6 Falcon Finance Falcon Finance +11.18%
#7 龙虾 (Lobster) 龙虾 (Lobster) +10.89%
#8 Cross Cross +10.81%
#9 Power Protocol Power Protocol +10.32%
#10 AI Rig Complex AI Rig Complex +10.27%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Rank in Stocks #37018
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Share Price
$0.25974701
Last synced: 2025-01-06
Market Cap
$2.04M
Change (1 day)
0.74%
Change (1 year)
0.00%
Country
FR
Trade Acticor Biotech SAS (ALACT)

Category

Healthcare
P/E ratio for Acticor Biotech SAS (ALACT)
P/E ratio as of September 2026 TTM: -166.67
According to Acticor Biotech SAS latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -166.67. At the end of 2022 the company had a P/E ratio of -4.69.
P/E ratio history for Acticor Biotech SAS from 2010 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) -166.67 8,765.25%
2023 -1.88 -59.96%
2022 -4.69 65.91%
2021 -2.83 -51.76%
2020 -5.86 -19.83%
2019 -7.31 102.29%
2018 -3.61 60.31%
2017 -2.25 -95.44%
2016 -49.37 186.58%
2015 -17.23 -28.72%
2014 -24.17 -302.58%
2013 11.93 14.37%
2012 10.43 -24.95%
2011 13.90 -82.70%
2010 80.32 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.99 -118.00%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.30 -121.78%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.34 -86.00%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -18.38 -88.97%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.